<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Tonix Pharmaceuticals Holding Corp.

    Tonix Pharmaceuticals Holding Corp.

    Tonix is a clinical-stage biopharmaceutical company focused on discovering and dev...

    Tonix is a clinical-stage biopharmaceutical com...

    Filing Type:    PU
    Antares Pharma, Inc.

    Antares Pharma, Inc.

    Antares Pharma is a specialty pharmaceutical company that combines drug developmen...

    Antares Pharma is a specialty pharmaceutical co...

    Filing Type:    PU
    Savara, Inc.

    Savara, Inc.

    Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex,...

    Savara is an orphan lung disease company. Savar...

    Filing Type:    PU
    Hancock Jaffe Laboratories, Inc.

    Hancock Jaffe Laboratories, Inc.

    HJLI specializes in developing and manufacturing bioprosthetic medical devices to ...

    HJLI specializes in developing and manufacturin...

    Filing Type:    PU
    Delee Corp

    Delee Corp

    At Delee, we aim to radically change the way cancer is detected, monitored and tre...

    At Delee, we aim to radically change the way ca...

    Fundraising Status:    EC
    Filing Type:    CF
    Personalis, Inc.

    Personalis, Inc.

    Personalis, Inc. is a growing cancer genomics company transforming the development...

    Personalis, Inc. is a growing cancer genomics c...

    Filing Type:    PU
    Gritstone Oncology, Inc.

    Gritstone Oncology, Inc.

    Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...

    Gritstone Oncology is developing tumor-specific...

    Filing Type:    PU
    Merus N.V.

    Merus N.V.

    Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...

    Merus is a clinical-stage immuno-oncology compa...

    Filing Type:    PU
    Vir Biotechnology, Inc.

    Vir Biotechnology, Inc.

    Vir integrates diverse innovations in science, technology, and medicine to transfo...

    Vir integrates diverse innovations in science, ...

    Filing Type:    PU
    NuCana plc

    NuCana plc

    We are a clinical-stage biopharmaceutical company focused on significantly improvi...

    We are a clinical-stage biopharmaceutical compa...

    Filing Type:    PU
    H & G Science, Inc.

    H & G Science, Inc.

    H&G Science aims to facilitate the safe and effective treatment of diseases. Our g...

    H&G Science aims to facilitate the safe and eff...

    Amount Raised:    $24,000.00
    Fundraising Status:    EC
    Filing Type:    CF
    NextCure, Inc.

    NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering an...

    NextCure is a clinical-stage biopharmaceutical ...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.